Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant.

Persaud AK, Li J, Johnson JA, Seligson N, Sborov DW, Duah E, Cho YK, Wang D, Phelps MA, Hofmeister CC, Poi MJ.

Mol Carcinog. 2019 Sep 22. doi: 10.1002/mc.23121. [Epub ahead of print]

PMID:
31544312
2.

Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice.

Hughes JH, Upton RN, Reuter SE, Rozewski DM, Phelps MA, Foster DJR.

Cancer Chemother Pharmacol. 2019 Sep 6. doi: 10.1007/s00280-019-03941-z. [Epub ahead of print]

PMID:
31493176
3.

Optimising time samples for determining area under the curve of pharmacokinetic data using non-compartmental analysis.

Hughes JH, Upton RN, Reuter SE, Phelps MA, Foster DJR.

J Pharm Pharmacol. 2019 Nov;71(11):1635-1644. doi: 10.1111/jphp.13154. Epub 2019 Aug 14.

PMID:
31412422
4.

ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model.

Chiang CL, Goswami S, Frissora FW, Xie Z, Yan PS, Bundschuh R, Walker LA, Huang X, Mani R, Mo XM, Baskar S, Rader C, Phelps MA, Marcucci G, Byrd JC, Lee LJ, Muthusamy N.

Blood. 2019 Aug 1;134(5):432-444. doi: 10.1182/blood.2018882290. Epub 2019 May 31.

PMID:
31151986
5.
6.

Population pharmacokinetics of lenalidomide in patients with B-cell malignancies.

Hughes JH, Phelps MA, Upton RN, Reuter SE, Gao Y, Byrd JC, Grever MR, Hofmeister CC, Marcucci G, Blum W, Blum KA, Foster DJR.

Br J Clin Pharmacol. 2019 May;85(5):924-934. doi: 10.1111/bcp.13873. Epub 2019 Feb 27.

PMID:
30672004
7.

SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion.

Lu C, Yang D, Klement JD, Oh IK, Savage NM, Waller JL, Colby AH, Grinstaff MW, Oberlies NH, Pearce CJ, Xie Z, Kulp SK, Coss CC, Phelps MA, Albers T, Lebedyeva IO, Liu K.

Cancer Immunol Res. 2019 Mar;7(3):414-427. doi: 10.1158/2326-6066.CIR-18-0126. Epub 2019 Jan 4.

PMID:
30610059
8.

A Single Nucleotide Polymorphism in SLC7A5 Was Associated With Clinical Response in Multiple Myeloma Patients.

Poi MJ, Li J, Johnson JA, Cho YK, Sborov DW, Phelps MA, Hofmeister CC.

Anticancer Res. 2019 Jan;39(1):67-72. doi: 10.21873/anticanres.13080.

PMID:
30591441
9.

Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant.

Cho YK, Irby DJ, Li J, Sborov DW, Mould DR, Badawi M, Dauki A, Lamprecht M, Rosko AE, Fernandez S, Hade EM, Hofmeister CC, Poi M, Phelps MA.

CPT Pharmacometrics Syst Pharmacol. 2018 Nov;7(11):748-758. doi: 10.1002/psp4.12345. Epub 2018 Oct 20.

10.

Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy?

Coss CC, Clinton SK, Phelps MA.

Clin Cancer Res. 2018 Dec 1;24(23):5787-5789. doi: 10.1158/1078-0432.CCR-18-1847. Epub 2018 Jul 17.

PMID:
30018117
11.

Phyllanthusmin Derivatives Induce Apoptosis and Reduce Tumor Burden in High-Grade Serous Ovarian Cancer by Late-Stage Autophagy Inhibition.

Young AN, Herrera D, Huntsman AC, Korkmaz MA, Lantvit DD, Mazumder S, Kolli S, Coss CC, King S, Wang H, Swanson SM, Kinghorn AD, Zhang X, Phelps MA, Aldrich LN, Fuchs JR, Burdette JE.

Mol Cancer Ther. 2018 Oct;17(10):2123-2135. doi: 10.1158/1535-7163.MCT-17-1195. Epub 2018 Jul 17.

12.

CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128.

Badawi M, Kim J, Dauki A, Sutaria D, Motiwala T, Reyes R, Wani N, Kolli S, Jiang J, Coss CC, Jacob ST, Phelps MA, Schmittgen TD.

Oncotarget. 2018 May 25;9(40):26032-26045. doi: 10.18632/oncotarget.25430. eCollection 2018 May 25.

13.

Author Correction: Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration.

Markowitz J, Wang J, Vangundy Z, You J, Yildiz V, Yu L, Foote IP, Branson OE, Stiff AR, Brooks TR, Biesiadecki B, Olencki T, Tridandapani S, Freitas MA, Papenfuss T, Phelps MA, Carson WE.

Sci Rep. 2018 Mar 6;8(1):4203. doi: 10.1038/s41598-018-21306-z.

14.

Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration.

Markowitz J, Wang J, Vangundy Z, You J, Yildiz V, Yu L, Foote IP, Branson OE, Stiff AR, Brooks TR, Biesiadecki B, Olencki T, Tridandapani S, Freitas MA, Papenfuss T, Phelps MA, Carson WE.

Sci Rep. 2017 Nov 13;7(1):15424. doi: 10.1038/s41598-017-14970-0. Erratum in: Sci Rep. 2018 Mar 6;8(1):4203.

15.

Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.

Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, Phelps MA, Houghton P, London CA.

PLoS One. 2017 Jul 27;12(7):e0181885. doi: 10.1371/journal.pone.0181885. eCollection 2017.

16.

Low active loading of cargo into engineered extracellular vesicles results in inefficient miRNA mimic delivery.

Sutaria DS, Jiang J, Elgamal OA, Pomeroy SM, Badawi M, Zhu X, Pavlovicz R, Azevedo-Pouly ACP, Chalmers J, Li C, Phelps MA, Schmittgen TD.

J Extracell Vesicles. 2017 Jun 14;6(1):1333882. doi: 10.1080/20013078.2017.1333882. eCollection 2017.

17.

Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells.

Zhu X, Badawi M, Pomeroy S, Sutaria DS, Xie Z, Baek A, Jiang J, Elgamal OA, Mo X, Perle K, Chalmers J, Schmittgen TD, Phelps MA.

J Extracell Vesicles. 2017 Jun 6;6(1):1324730. doi: 10.1080/20013078.2017.1324730. eCollection 2017.

18.

A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.

Maly JJ, Christian BA, Zhu X, Wei L, Sexton JL, Jaglowski SM, Devine SM, Fehniger TA, Wagner-Johnston ND, Phelps MA, Bartlett NL, Blum KA.

Clin Lymphoma Myeloma Leuk. 2017 Jun;17(6):347-353. doi: 10.1016/j.clml.2017.05.008. Epub 2017 May 22.

19.

G-CSF improves safety when you start the day after autologous transplant in multiple myeloma.

Sborov DW, Cho YK, Cottini F, Hade EM, Lamprecht M, Tackett K, Sharma N, Williams N, Li J, Devine S, Poi M, Phelps MA, Hofmeister CC.

Leuk Lymphoma. 2017 Dec;58(12):2947-2951. doi: 10.1080/10428194.2017.1318436. Epub 2017 May 16. No abstract available.

20.

Rituximab immunotherapy: it's getting personal.

Phelps MA.

Blood. 2017 May 11;129(19):2595-2596. doi: 10.1182/blood-2017-03-772061. No abstract available.

PMID:
28495922
21.

Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide.

Bins S, van Doorn L, Phelps MA, Gibson AA, Hu S, Li L, Vasilyeva A, Du G, Hamberg P, Eskens F, de Bruijn P, Sparreboom A, Mathijssen R, Baker SD.

Clin Transl Sci. 2017 Jul;10(4):271-279. doi: 10.1111/cts.12458. Epub 2017 Mar 31.

22.

Achieving the Promise of Therapeutic Extracellular Vesicles: The Devil is in Details of Therapeutic Loading.

Sutaria DS, Badawi M, Phelps MA, Schmittgen TD.

Pharm Res. 2017 May;34(5):1053-1066. doi: 10.1007/s11095-017-2123-5. Epub 2017 Mar 17. Review.

23.

Plasma pharmacokinetics and bioavailability of verticillin A following different routes of administration in mice using liquid chromatography tandem mass spectrometry.

Wang J, Zhu X, Kolli S, Wang H, Pearce CJ, Oberlies NH, Phelps MA.

J Pharm Biomed Anal. 2017 May 30;139:187-192. doi: 10.1016/j.jpba.2017.02.051. Epub 2017 Mar 1.

24.

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.

Sborov DW, Canella A, Hade EM, Mo X, Khountham S, Wang J, Ni W, Poi M, Coss C, Liu Z, Phelps MA, Mortazavi A, Andritsos L, Baiocchi RA, Christian BA, Benson DM, Flynn J, Porcu P, Byrd JC, Pichiorri F, Hofmeister CC.

Leuk Lymphoma. 2017 Oct;58(10):2310-2318. doi: 10.1080/10428194.2017.1298751. Epub 2017 Mar 7.

25.

Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial.

Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Tackett K, Williams N, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Hofmeister CC, Phelps MA.

Clin Pharmacol Ther. 2017 Sep;102(3):511-519. doi: 10.1002/cpt.644. Epub 2017 May 26.

26.

Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant.

Poi MJ, Li J, Sborov DW, VanGundy Z, Cho YK, Lamprecht M, Pichiorri F, Phelps MA, Hofmeister CC.

Mol Carcinog. 2017 Jul;56(7):1722-1732. doi: 10.1002/mc.22626. Epub 2017 Feb 16.

PMID:
28150872
27.

Discovery of Anticancer Agents of Diverse Natural Origin.

Kinghorn AD, DE Blanco EJ, Lucas DM, Rakotondraibe HL, Orjala J, Soejarto DD, Oberlies NH, Pearce CJ, Wani MC, Stockwell BR, Burdette JE, Swanson SM, Fuchs JR, Phelps MA, Xu L, Zhang X, Shen YY.

Anticancer Res. 2016 Nov;36(11):5623-5637. Review.

28.

Preferential Delivery of an Opioid Antagonist to the Fetal Brain in Pregnant Mice.

Oberdick J, Ling Y, Phelps MA, Yudovich MS, Schilling K, Sadee W.

J Pharmacol Exp Ther. 2016 Jul;358(1):22-30. doi: 10.1124/jpet.115.231902. Epub 2016 May 5.

29.

Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma.

Mani R, Yan R, Mo X, Chen CS, Phelps MA, Klisovic R, Byrd JC, Kisseberth WC, London CA, Muthusamy N.

Vet Comp Oncol. 2017 Sep;15(3):1115-1118. doi: 10.1111/vco.12221. Epub 2016 May 2.

30.

The end of a monolith: Deconstructing the Cnn-Polo interaction.

Eisman RC, Phelps MA, Kaufman TC.

Fly (Austin). 2016 Apr 2;10(2):60-72. doi: 10.1080/19336934.2016.1178419. Epub 2016 Apr 20.

31.

Discovery and Mechanism of Highly Efficient Cyclic Cell-Penetrating Peptides.

Qian Z, Martyna A, Hard RL, Wang J, Appiah-Kubi G, Coss C, Phelps MA, Rossman JS, Pei D.

Biochemistry. 2016 May 10;55(18):2601-12. doi: 10.1021/acs.biochem.6b00226. Epub 2016 Apr 28.

PMID:
27089101
32.

In vitro immunotoxicity assessment of culture-derived extracellular vesicles in human monocytes.

Rosas LE, Elgamal OA, Mo X, Phelps MA, Schmittgen TD, Papenfuss TL.

J Immunotoxicol. 2016 Sep;13(5):652-65. doi: 10.3109/1547691X.2016.1148089. Epub 2016 Apr 14.

33.

Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents.

Cheng H, Xie Z, Jones WP, Wei XT, Liu Z, Wang D, Kulp SK, Wang J, Coss CC, Chen CS, Marcucci G, Garzon R, Covey JM, Phelps MA, Chan KK.

AAPS J. 2016 May;18(3):737-45. doi: 10.1208/s12248-016-9876-3. Epub 2016 Mar 4.

34.

Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.

Harshman SW, Canella A, Ciarlariello PD, Agarwal K, Branson OE, Rocci A, Cordero H, Phelps MA, Hade EM, Dubovsky JA, Palumbo A, Rosko A, Byrd JC, Hofmeister CC, Benson DM Jr, Paulaitis ME, Freitas MA, Pichiorri F.

J Proteomics. 2016 Mar 16;136:89-98. doi: 10.1016/j.jprot.2015.12.016. Epub 2016 Jan 13.

35.
36.

Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer.

Ahn DH, Li J, Wei L, Doyle A, Marshall JL, Schaaf LJ, Phelps MA, Villalona-Calero MA, Bekaii-Saab T.

Sci Rep. 2015 Jul 10;5:12122. doi: 10.1038/srep12122.

37.

ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo.

Mani R, Chiang CL, Frissora FW, Yan R, Mo X, Baskar S, Rader C, Klisovic R, Phelps MA, Chen CS, Lee RJ, Byrd JC, Baiocchi R, Lee LJ, Muthusamy N.

Exp Hematol. 2015 Sep;43(9):770-4.e2. doi: 10.1016/j.exphem.2015.04.008. Epub 2015 Apr 29.

PMID:
25937048
38.

The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.

Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA.

Br J Haematol. 2015 Jun;169(5):701-10. doi: 10.1111/bjh.13354. Epub 2015 Apr 7.

PMID:
25847298
39.

Pharmacokinetics of intra-articular betamethasone sodium phosphate and betamethasone acetate and endogenous hydrocortisone suppression in exercising horses.

Menendez MI, Phelps MA, Bertone AL.

J Vet Pharmacol Ther. 2016 Feb;39(1):22-6. doi: 10.1111/jvp.12229. Epub 2015 Apr 3.

PMID:
25847081
40.

Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.

Ranganathan P, Yu X, Santhanam R, Hofstetter J, Walker A, Walsh K, Bhatnagar B, Klisovic R, Vasu S, Phelps MA, Devine S, Shacham S, Kauffman M, Marcucci G, Blum W, Garzon R.

Blood. 2015 Apr 23;125(17):2689-92. doi: 10.1182/blood-2014-10-607648. Epub 2015 Feb 25.

41.

Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.

Awan FT, Flynn JM, Jones JA, Andritsos LA, Maddocks KJ, Sass EJ, Lucas MS, Chase W, Waymer S, Ling Y, Jiang Y, Phelps MA, Byrd JC, Lucas DM, Woyach JA.

Leuk Lymphoma. 2015;56(10):2834-40. doi: 10.3109/10428194.2015.1014368. Epub 2015 Mar 11.

42.

Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).

Maddocks K, Wei L, Rozewski D, Jiang Y, Zhao Y, Adusumilli M, Pierceall WE, Doykin C, Cardone MH, Jones JA, Flynn J, Andritsos LA, Grever MR, Byrd JC, Johnson AJ, Phelps MA, Blum KA.

Am J Hematol. 2015 Apr;90(4):327-33. doi: 10.1002/ajh.23946. Epub 2015 Feb 25.

43.

Liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of simvastatin, lovastatin, atorvastatin, and their major metabolites in human plasma.

Wang J, Luzum JA, Phelps MA, Kitzmiller JP.

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Mar 1;983-984:18-25. doi: 10.1016/j.jchromb.2014.12.029. Epub 2015 Jan 13.

44.

OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells.

Liu TM, Ling Y, Woyach JA, Beckwith K, Yeh YY, Hertlein E, Zhang X, Lehman A, Awan F, Jones JA, Andritsos LA, Maddocks K, MacMurray J, Salunke SB, Chen CS, Phelps MA, Byrd JC, Johnson AJ.

Blood. 2015 Jan 8;125(2):284-95. doi: 10.1182/blood-2014-06-583518. Epub 2014 Oct 7.

45.

Comparison of high-dose intermittent and low-dose continuous oral artemisinin in dogs with naturally occurring tumors.

Hosoya K, Couto CG, London CA, Kisseberth WC, Phelps MA, Dalton JT.

J Am Anim Hosp Assoc. 2014 Nov-Dec;50(6):390-5. doi: 10.5326/JAAHA-MS-6145. Epub 2014 Sep 23.

PMID:
25251432
46.

A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia.

Maddocks K, Ruppert AS, Browning R, Jones J, Flynn J, Kefauver C, Gao Y, Jiang Y, Rozewski DM, Poi M, Phelps MA, Harper E, Johnson AJ, Byrd JC, Andritsos LA.

Leuk Res. 2014 Sep;38(9):1025-9. doi: 10.1016/j.leukres.2014.05.011. Epub 2014 May 29.

47.

Establishing a clinical pharmacology fellowship program for physicians, pharmacists, and pharmacologists: a newly accredited interdisciplinary training program at the Ohio State University.

Kitzmiller JP, Phelps MA, Neidecker MV, Apseloff G.

Adv Med Educ Pract. 2014 Jun 23;5:191-6. doi: 10.2147/AMEP.S60986. eCollection 2014.

48.

Irinotecan pharmacogenetics: a finished puzzle?

Phelps MA, Sparreboom A.

J Clin Oncol. 2014 Aug 1;32(22):2287-9. doi: 10.1200/JCO.2014.56.3387. Epub 2014 Jun 23. No abstract available.

PMID:
24958823
49.

Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.

Mani R, Mao Y, Frissora FW, Chiang CL, Wang J, Zhao Y, Wu Y, Yu B, Yan R, Mo X, Yu L, Flynn J, Jones J, Andritsos L, Baskar S, Rader C, Phelps MA, Chen CS, Lee RJ, Byrd JC, Lee LJ, Muthusamy N.

Leukemia. 2015 Feb;29(2):346-55. doi: 10.1038/leu.2014.199. Epub 2014 Jun 20.

50.

Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry.

Mao Y, Wang J, Zhao Y, Yan R, Li H, Chen CS, Lee RJ, Byrd JC, Lee LJ, Muthusamy N, Phelps MA.

J Pharm Biomed Anal. 2014 Sep;98:160-5. doi: 10.1016/j.jpba.2014.05.022. Epub 2014 May 23.

Supplemental Content

Loading ...
Support Center